What is the clinical effectiveness and cost-effectiveness of nebulised saline in patients with chronic obstructive pulmonary disease? (MucAct COPD Trial) We want to study whether breathing in salty water through a nebuliser can help patients with Chronic Obstructive Pulmonary Disease (COPD) cough up phlegm, make them feel better and cut down the number of chest infections. We also would like to know whether this is better than taking tablets (carbocisteine), also thought to help patients clear phlegm from the airways. Chief Investigator: Professor Adam Hill Image Number and location of participating sites (by region/ country): 20 UK Sites EudraCT number: 2020-001949-39 ISRCTN number: TBC Funder: National Institute for Health Research Health Technology Assessment Programme (NIHR HTA) Start and End date Of grant award: 01 June 2020 - 30 June 2025 Of recruitment: October 2021 - 01 December 2023 Current Status: Closed to recruitment Trial Website: No Email: MucActCOPD@ed.ac.uk UK GDPR Privacy Statement: As part of Patient Information Sheet Sponsor: ACCORD (https://www.accord.ed.ac.uk/) Chief Investigator: Professor Adam Hill Address: 102 West Port, Edinburgh, EH3 9DN Email: adam.hill@nhs.scot Trial Manager: Bea Selby Email: MucActCOPD@ed.ac.uk Research Nurse: Sam Donaldson Email: sam.donaldson1@nhs.net and Andrea Clarke Email: andrea.clarke8@nhs.net ECTU involvement: Trial management / Statistics / Health Economics / Data base This article was published on 2024-09-24